Clinical study to Evaluate Safety and Efficacy of Boozidaan (Pyrethrum indicum) in the management of Niqris Muzmin (Chronic Gout)

Abstract

Objectives: The objectives of this study were to observe the Efficacy of unani pharmacopoeial formulation Boozidan (Pyrethrum indicum) for the management of Niqris Muzmin (Chronic gout) and to observe any concomitant and adverse effects of formulation.


Methods: This single blind, randomized and standard control clinical study was conducted between April 2021 to October 2021 for a period of 28 days. 60 patients diagnosed with chronic gout were divided into two groups, 30 Test group and 30 Control group. The test group was administered with 5g boozidaan in powder form once daily with water and the patients of control group were given tablet febuxostat 80mg once daily. Patients were followed up and improvements in subjective parameters were assessed weekly at 7th, 14th, 21st, and 29th day. Objective parameters were assessed at the baseline and at 29th day. The data obtained was subjected to statistical analysis.


Results: Both the test and control drug were effective in reducing Serum uric acid level, ESR and CRP levels.  A significant improvement in subjective and objective parameters was observed in both test and control groups and no adverse effects were observed during and after the study.


However, the test drug had superior efficacy in reducing the objective parameters and it was statistically significant (p-value<0.0001).


Conclusion: Both Boozidaan and Febuxostat were safe and significantly effective in resolving the symptoms and signs of gouty arthritis and both have significant effect on reducing serum uric acid level.


Keywords: Boozidaan, Chronic gout, Niqris, Febuxostat, serum uric acid, unani medicine

Keywords: Boozidaan, Chronic gout, Niqris, Febuxostat, serum uric acid, unani medicine

Downloads

Download data is not yet available.

Author Biographies

JOSEE AMIN, Assistant professor, Department of Mahiat ul Amraz , Kashmir Tibbia college, hospital and research centre, University of Kashmir,Srinagar, Jammu and Kashmir, India.

 Assistant professor, Department of Mahiat ul Amraz , Kashmir Tibbia college, hospital and research centre, University of Kashmir,Srinagar, Jammu and Kashmir, India.

Naquibul Islam, Ex- HOD, Professor, Department of Mo‘ālajāt, Regional Research Institute of Unani Medicine,Srinagar, J&K, India

Ex- HOD, Professor, Department of Mo‘ālajāt, Regional Research Institute of Unani Medicine,Srinagar, J&K, India 

Towseef Amin Rafeeqi, Research officer, Biochemistry, Regional Research Institute of Unani Medicine, Srinagar, J&K, India

Research officer, Biochemistry, Regional Research Institute of Unani Medicine, Srinagar, J&K, India

References

1. Ralston, S. H., Penman, I. D., Strachan, M. W. J., & Hobson, R. (Eds.). Davidson's principles and practice of medicine Edn.23rd, Churchill Livingstone, Elsevier Health Sciences,2018, 1015.
2. Munjal YP, Sharma SK, Agarwal AK, Gupta P, Kamath SA, Nadkar MY, et al. API Textbook of Medicine. Edn 9, Vol. 2, The Association of Physicians of India, JP Brothers Medical Publishers (P) Ltd, 2012,
3.Qaseem A,Harris RP, Forciea MA, et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med.2017;166:58-68. https://doi.org/10.7326/M16-0570 PMid:27802508
4. Pisaniello HL, Lester S, Gonzalez-Chica D, Stocks N, Longo M, Sharplin GR, Dal Grande E, Gill TK, Whittle SL, Hill CL. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study. Arthritis Res Ther. 2018 Jul 11;20(1):143. https://doi.org/10.1186/s13075-018-1633-9 PMid:29996922 PMCid:PMC6042461
5. Fernández MG, Escudero PG, García EB, Ruiz AA, Ruiz FP. Early-Onset Gout: What is behind this Pathology?. Am J Arthritis. 2020; 4(1): 1016
6.Evans PL, Prior JA, Belcher J, et. al, Gender-specific risk factors for gout: a systematic review of cohort studies,Advances in Rheumatology 2019;59:1-12. https://doi.org/10.1186/s42358-019-0067-7 PMid:31234907
7. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):223. https://doi.org/10.1186/ar3199 PMid:21205285 PMCid:PMC3046529
8. Fang YJ, Chung YL, Lin CL, Lim YP. Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study. Biomed Res Int. 2020;2020:6358954. https://doi.org/10.1155/2020/6358954 PMid:32775432 PMCid:PMC7407011
9. Pascart T, Latourte A, Flipo RM, et al, 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy, Joint Bone Spine,2020;87(5):395-404. https://doi.org/10.1016/j.jbspin.2020.05.002 PMid:32422338
10.Kienhorst LB, Janssens HJ, Janssen M. Gout: A clinical overview and its association with cardiovascular diseases. World J Rheumatol 2014; 4(3): 62-71. https://doi.org/10.5499/wjr.v4.i3.62
11. Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective - A review. J Adv Res. 2017;8(5):495-511. https://doi.org/10.1016/j.jare.2017.04.008 PMid:28748116 PMCid:PMC5512152
12. Butler, F.; Alghubayshi, A.; Roman, Y. The Epidemiology and Genetics of Hyperuricemia and Gout across Major Racial Groups: A Literature Review and Population Genetics Secondary Database Analysis. J. Pers. Med. 2021;11(3): 231. https://doi.org/10.3390/jpm11030231 PMid:33810064 PMCid:PMC8005056
13. Roubenoff R. Gout and Hyperuricemia. Rheum Dis Clin. 1990; 16:539-50. https://doi.org/10.1016/S0889-857X(21)00887-5
14. Singh JA, Gaffo A. Gout epidemiology and comorbidities . Seminars in Arthritis and Rheumatism 2020;50(3): S11-S16. https://doi.org/10.1016/j.semarthrit.2020.04.008 PMid:32620196
15. Nuki G, Riches P.Changing paradigms in the management of gout The journal of the Royal College of Physicians of Edinburgh2020; 50(2):124-132. https://doi.org/10.4997/jrcpe.2020.209 PMid:32568281
16. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis research & therapy. 2006; 8 Suppl 1:S2 https://doi.org/10.1186/ar1907 PMid:16820041 PMCid:PMC3226107
17. Punzi L, Scanu A, Galozzi P, et al,One year in review 2020: gout. Clin Exp Rheumatol 2020;38:807-821.
18. Igel TF, Krasnokutsky S, Pillinger MH. Recent advances in understanding and managing gout. F1000Res. 2017;6:247. https://doi.org/10.12688/f1000research.9402.1 PMid:28357052 PMCid:PMC5357039
19. Underwood, C.E., 2000, General and Systemic Pathology. 3rd ed. Churchill Livingstone; 726-27,131-132,577 .
20. Li Q, Li X, Kwong JS, et al. Diagnosis and treatment for hyperuricaemia and gout: a protocol for a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2017;7(6):e014928. https://doi.org/10.1136/bmjopen-2016-014928 PMid:28645962 PMCid:PMC5623447
21. Koto R, Nakajima A, Horiuchi H, Yamanaka H. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data, Modern Rheumatology, 2021;31;1:261-269. https://doi.org/10.1080/14397595.2020.1784556 PMid:32552370
22. Rothenbacher D & Primatesta P, Ferreira A, et al,. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford, England). 2011;50:973-81. https://doi.org/10.1093/rheumatology/keq363 PMid:21228059
23. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. Edn 18, Vol. 1, McGraw-Hill Companies, USA, 2012, 646-711.
24. Tripathi, K.D. (2013) Essentials of Medical Pharmacology. 7th Edition, Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, 210-217. https://doi.org/10.5005/jp/books/12256
25. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review. Rheumatology 2006; 45(11):1422-1431. https://doi.org/10.1093/rheumatology/kel071 PMid:16632483
26. Warner E.C. Savill's system of Clinical Medicine.14th ed.,India; 1964:417,890-893,909-911.
27. Majusi Ali Bin Abbas. Kamilus Sana (Urdu Translation by Hakeem Ghulam Hussain Kintoori).Vol II.,New Dehli: Idara Kitabu sh Shifa;2010:507-514
28. Maddison P.J. et al. Oxford Textbook of Rheumatology. Vol II., London: Oxford University Press; 1993:983-988.
29. Syngle Ashit, Deodhar SD. Rheumatology Principles and Practice. 1st ed..New Dehli: Jaypee Brothers Medical Publisher (P) Ltd; 2010:190-206). https://doi.org/10.5005/jp/books/11169_19
30. Goldman Lee, Ausiello Denis. Cecil Text Book of Medicine. 23rd ed.,Vol II.,Philadalphia:Saunders Elsevier; 2007 2069-2075,3181-3185.;
31. Akhtar H, Siddiqi M. The clinical study of primary gout and comparative evaluation of Habb-E-Suranjan with allopurinol in its managementJournal of Pharmacognosy and Phytochemistry 2019; 8(4):84-90. https://doi.org/10.31254/jahm.2019.5303
32. Khan Hakim Waliullah. Ghina Muna Ma Tarjuma-e-Minhajul Ilaj (Original author Abu Mansoor-ul-Hasan Bin Nooh Qamri):276-284.
33. Rhazi Abu Bakr Mohd Bin Zakariya. Kitabul Hawi (Urdu Translation)Vol. XI.,New Dehli:CCRUM,Ministry of Health & Family Walfare DOI;2004:75-171.
34. Rhazi Abu Bakr Mohd Bin Zakariya. Kitabul al Mansoori (Urdu Translation)., New Dehli:CCRUM Ministry of Health and Family Welfare, Government of India;1991:136,143, 145,391-394.
35. Looqa Qusta bin. Risala Fi Auja Al-Niqris ( Urdu Translation by prof Hkm Syed Zillur Rehman).,Aligarh:Ibn Sin Academy, Dodhpur;2007:68-137.
36. Schmitz Paul G, Martin Kewin J. Internal Medicine just the facts, Mc Graw Hill Medical Library of congress cataloging in Data; 2008:733-738.
37. Nuki, G.; Simkin, P.A. A Concise History of Gout and Hyperuricemia and Their Treatment. Arthritis Res. Ther. 2006;8 (Suppl. S1):S1. https://doi.org/10.1186/ar1906 PMid:16820040 PMCid:PMC3226106
38. Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout: new insights into pathogenesis and treatment. Bull NYM Hosp Jt Dis.2007; 65(3):215-21.
39. Omole OB, Ogunbanjo GA. The evolution of gout (an old lifestyle disease). SA Fam Pract 2009;51(5):396-398. https://doi.org/10.1080/20786204.2009.10873890
40. Wortmann Rober L, Kelley William N. Kelly's Textbook of Rheumatology 7th ed.Vol.II., Pennsylvania:Elsevier Saunders;2005: 1402-1426.
41. Fourtunas Costas. Perceptions of gout (podagra) during the Byzantine era, with a special focus on a poem by Michael Psellus. JNephrol 2013; 26(suppl 22): S 110-S112.
42. Majusi Ali Bin Abbas. Kamilus Sana (Urdu Translation by Hakeem Ghulam Hussain Kintoori).Vol II.,New Dehli: Idara Kitabu sh Shifa;2010:507-514.
43. Schmitz Paul G, Martin Kewin J. Internal Medicine just the facts, Mc Graw Hill Medical Library of congress cataloging in Data; 2008:733-738.
44. Sina Ibn.Alqanoon fit Tibb (Urdu Translation by Hakeem Ghulam Husain Kintoori) Vol-3., New Dehli:Idara kitab us shifa;YNM:1121-1123.
45. Aafreen S, Siddiqui MA, Quamri MA, et al. Efficacy of Unani Formulations in Waja-ul-Khasirah (Low Back Pain) - A Randomised Double Dummy Clinical Trial International Journal of Research & Review (www.ijrrjournal.com) 2019;6(9):87-96.
46. Jabeen A, Mansoori SA, Jilani S, Azam R Management of cervical spondylosis in unani system of medicine The Pharma Innovation Journal 2018; 7(10): 655-660.
47. Ansari AA, Sabir A , "Scientific study of Unani formulations In the cases of osteoporosis", Pharmacophore 2017; 8(2):1-10.
48. Singh S,Nair V,Gupta YKAntiarthritic activity of Majoon Suranjan (a polyherbal Unani formulation) in rat Indian J Med Res 2011;134:384-388.
49. Mohammad SA,Ansari AN Efficacy of Qai, Munzij wa Mus'hil-e-Balgham and Dalk with Roghan-e-Chobchini in Waja-ur-Rukba (Knee Osteoarthritis) 2020; 7(1):887-896.
50. Ghani,HMN,Khazain al Adwiya. New Delhi:Idara Kitabul Shifa;Vol II:402
51. Ibn Baytar, Al Jamiul Mufradat al-Adwiya wa-al-Aghdhiya(Urdu translation), New Delhi: CCRUM; VOL I :307
52. Kabiral-Din, MakhzanulMufaridat.Lahore:SidiquiPublisher House:117
53.Muḥammad Jamīl Mirzā; Muʻīnuddīn ʻAlīg Qarābādīn-i sarkārī. Central Council for Research in Unani Medicine (India), 2006.p 24.
54. Hakim A, Bustanul Mufradat, New Delhi, IdaraKitab ul Shifa, 2002, p 142
55. Khare CP. Indian Medicinal Plants . Springer Verlag, New York ist edition, jun 2008,p144 https://doi.org/10.1007/978-0-387-70638-2 PMCid:PMC2705749
56. Kabeeruddin M. Ilmul Advia Nafeesi, Ajaz Publishing House, New Delhi, 2007, p 92.
57. Ibn Baitar (1985) Al Jame li Mufridat al-Advia wal-Aghziya. Central Council for Research in Unani Medicine, New Delhi, vol. 1, pp. 29-345.
58. Safiuddin AS, Unani Advia Mufrada, Qawmi Council Barae Farogh Urdu Zaban, 2010, p 83.
59. Ansari MY, Munafe-ul-Mufredat, Kitab Ush-shifa 1 January 2009,p 269,304
60. Arzani MA. Qarabadeene Qadri . New Delhi: CCRUM; 2009.414.
61. Hakeem MA. Mufradat-e-Azizi. New Delhi, CCRUM, p. 85.
62. Ghulam NM. Makhzane Mufradat wa Murakkabat. 2nd ed. New Delhi: CCRUM, Ministry of Health and Family Welfare, Gov. of India; 2007. P 70.
63.http://www.druginfosys.com/herbal/herb.aspx?code=85&name=pyrethrum%20indicum%20linn.&type=1
64. Wadud A. Text book of Single Drugs, Frontline publications, Hyderabad, ist ed, p 299, 300.
65. Baghdadi IH.Kitab al- Mukhtarat Fit Tibb (urdu translation);New Delhi, CCRUM, Part II, P-81
66. Al-Maghrabi ASI. Kitab al-Fatah fi'l Tadawi Min Jamee Sunuf al-Amraz wa al-Shaksawi (Urdu translation by Bari A). Delhi: NCPC Printers; 2007: 72.
67. Souhami RL,Moxham J. Textbook of Medicine.3rd ed.Churchill Livingstone Library of Congress Cataloguing in Publication Data;1997:949-953
68. Kabeeruddin Hakim Mohd. Tarjuma-e-Kabeer (Sharah-e-Asbab wa Alamat)., part III.,Hyderabad:Hikmat Book Depot;1916:189-191
Crossmark
Statistics
81 Views | 8 Downloads
How to Cite
1.
AMIN J, Islam N, Rafeeqi TA. Clinical study to Evaluate Safety and Efficacy of Boozidaan (Pyrethrum indicum) in the management of Niqris Muzmin (Chronic Gout). JDDT [Internet]. 15Mar.2024 [cited 19Apr.2024];14(3):8-1. Available from: https://jddtonline.info/index.php/jddt/article/view/6447